Cite
HARVARD Citation
Lampl, C. et al. (2022). Efficacy and quality‐of‐life improvements with fremanezumab treatment in patients with difficult‐to‐treat migraine with associated neurological dysfunction. European journal of neurology. pp. 2129-2137. [Online].